A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment

Cancer Discovery

Volumn 1, Issue 1, 2011, Pages 68-77

  Platz, Elizabeth A ^a,b,c   Yegnasubramanian, Srinivasan ^b   Liu, Jun O ^b,c   Chong, Curtis R ^c   Shim, Joong Sup ^c   Kenfield, Stacey A ^d   Stampfer, Meir J ^d   Willett, Walter C ^d   Giovannucci, Edward ^d   Nelson, William G ^b,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; DIGOXIN; LANATOSIDE;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CANCER RISK; CELL PROLIFERATION; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG POTENCY; DRUG SCREENING; EPIDEMILOGY; FOLLOW UP; HEART ARRHYTHMIA; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROSTATE CANCER; QUESTIONNAIRE;

CELL LINE, TUMOR; CELL PROLIFERATION; COHORT STUDIES; DIGOXIN; FOLLOW-UP STUDIES; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RISK FACTORS;

EID: 79959922456     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8274.CD-10-0020     Document Type: Article

References (27)

1. Scherer FM. The pharmaceutical industry-prices and progress. N Engl J Med 2004;351:927-32.
2. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85.
3. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673-83.
4. Chong CR, Sullivan DJ, Jr. New uses for old drugs. Nature 2007;448:645-6.
5. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the Health Professionals Follow-up Study. Int J Cancer 2007;121:1571-8.
6. Newman RA, Yang P, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 2008;8:36-49.
7. Prassas I, Diamandis EP. Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov 2008;7:926-35.
8. McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA. Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgenindependent, metastatic human prostate adenocarcinoma cells. Cancer Res 2000;60:3807-12.
9. Yeh JY, Huang WJ, Kan SF, Wang PS. Inhibitory effects of digitalis on the proliferation of androgen dependent and independent prostate cancer cells. J Urol 2001;166:1937-42.
10. Wang Z, Zheng M, Li Z, Li R, Jia L, Xiong X, et al. Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition. Cancer Res 2009;69:6556-64.
11. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A 2008;105:19579-86.
12. Lewinn EB. Gynecomastia during digitalis therapy; report of eight additional cases with liver-function studies. N Engl J Med 1953;248:316-20.
13. Benade LE, Talbot N, Tagliaferri P, Hardy C, Card J, Noda M, et al. Ouabain sensitivity is linked to ras-transformation in human HOS cells. Biochem Biophys Res Commun 1986;136:807-14.
14. Tagliaferri P, Yanagihara K, Ciardiello F, Talbot N, Flatow U, Benade L, et al. Effects of ouabain on NIH/3T3 cells transformed with retroviral oncogenes and on human tumor cell lines. Int J Cancer 1987;40:653-8.
15. Iglehart JD, Silver DP. Synthetic lethality-a new direction in cancerdrug development. N Engl J Med 2009;361:189-91.
16. Zavareh RB, Lau KS, Hurren R, Datti A, Ashline DJ, Gronda M, et al. Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. Cancer Res 2008;68:6688-97.
17. Selby JV, Friedman GD, Fireman BH. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res 1989;49:5736-47.
18. Haux J, Klepp O, Spigset O, Tretli S. Digitoxin medication and cancer; case control and internal dose-response studies. BMC Cancer 2001;1:11.
19. Bernstein L, Ross RK. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a casecontrol study in Los Angeles County. Cancer Res 1992;52:5510s-5s.
20. Van Den, Eeden SK, Friedman GD. Prescription drug screening for subsequent carcinogenicity. Pharmacoepidemiol Drug Saf 1995;4:275-87.
21. Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A. Risk factors for male breast cancer-a case-control study from Scandinavia. Acta Oncol 2001;40:467-71.
22. Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004;15:419-28.
23. Ahern TP, Lash TL, Sorensen HT, Pedersen L. Digoxin treatment is associated with an increased incidence of breast cancer: a populationbased case-control study. Breast Cancer Res 2008;10:R102.
24. The Merck Manuals Online Medical Library. 2009 [cited 2009 Sep 9]. Available from: http://www.merck.com/mmpe/lexicomp/digoxin. html
25. Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z, et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 2008;68:8954-67.
26. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-25.
27. Chan JM, Holick CN, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, et al. Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control 2006;17:199-208.